AC Immune SA

NASDAQ:ACIU   4:00:00 PM EDT
2.60
-0.16 (-5.80%)
4:31:59 PM EDT: $2.71 +0.11 (+4.23%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)217.23M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.06 Million
Adjusted EPS-$0.26
See more estimates
10-Day MA$2.69
50-Day MA$2.82
200-Day MA$3.32
See more pivots

AC Immune SA Stock, NASDAQ:ACIU

EPFL Innovation Park, Building B, Lausanne, Vaud 1015
Switzerland
Phone: +41.21.345.91.21
Number of Employees: 143

Description

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.